^
    14h
    A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=72, Not yet recruiting, GlaxoSmithKline
    New P1/2 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • Xtandi (enzalutamide) • leucovorin calcium • risvutatug rezetecan (GSK5764227)
    16h
    COLUMBIA 1: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (clinicaltrials.gov)
    P1/2, N=61, Active, not recruiting, MedImmune LLC | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • oleclumab (MEDI9447)
    20h
    Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup-Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOW. (PubMed, Cancer Res Treat)
    Patients were randomized 1:1 to receive zolbetuximab plus chemotherapy or placebo plus chemotherapy (mFOLFOX6 [modified folinic acid, 5-fluorouracil, and oxaliplatin] or CAPOX [capecitabine and oxaliplatin]). Zolbetuximab plus chemotherapy demonstrated favorable PFS and OS versus placebo plus chemotherapy in the Korean subgroup, with numerically greater efficacy compared with the overall pooled population. This may be potentially attributable to low rates of zolbetuximab discontinuation and toxicity management.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative • EGFR positive
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb)
    20h
    NPR3 promotes colorectal cancer cell proliferation, migration, invasion, and chemotherapy resistance. (PubMed, Biochim Biophys Acta Gen Subj)
    The LNMRGS is a robust prognostic signature for CRC. NPR3 plays a key role in metastatic progression and chemoresistance, suggesting it as a potential therapeutic target.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NPR3 (Natriuretic Peptide Receptor 3) • ITGB3 (Integrin Subunit Beta 3)
    |
    KRAS mutation
    |
    5-fluorouracil • oxaliplatin
    21h
    OrigAMI-5: A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • Rybrevant (amivantamab-vmjw)
    21h
    KEYNOTE 811: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) (clinicaltrials.gov)
    P3, N=738, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    21h
    Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=60, Completed, Guangxi Medical University | Unknown status --> Completed | Trial completion date: Jun 2022 --> Oct 2025
    Trial completion • Trial completion date
    |
    cisplatin • 5-fluorouracil • albumin-bound paclitaxel
    22h
    PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer (clinicaltrials.gov)
    P3, N=382, Not yet recruiting, Sun Yat-sen University
    New P3 trial • pMMR
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Hetronifly (serplulimab)
    1d
    Vascular Toxicities of Cancer Therapies: 2025 Update. (PubMed, Arterioscler Thromb Vasc Biol)
    5-fluorouracil and VEGF (vascular endothelial growth factor) inhibitors are the agents most commonly linked to abnormal vasoreactivity, whereas BCR-ABL (breakpoint cluster region-Abelson murine leukemia viral oncogene homolog) inhibitors and immune checkpoint inhibitors have been associated with accelerated atherosclerosis...Key contributors include endothelial injury and dysfunction, oxidative stress, and inflammation. An understanding of the mechanisms of vascular toxicities may facilitate optimal treatment and preventive strategies in patients with cancer.
    Review • Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    5-fluorouracil
    1d
    Protective Role of Boldine Against 5-Fluorouracil-Induced Nephrotoxicity: In Vitro and In Vivo Approach. (PubMed, J Biochem Mol Toxicol)
    Histopathological findings further confirmed that boldine preserved renal tissue integrity and prevented tubular and glomerular damage. Overall, boldine significantly protected against 5-FU-induced renal injury via anti-apoptotic, antioxidant, and anti-inflammatory mechanisms.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • JUN (Jun proto-oncogene)
    |
    5-fluorouracil
    1d
    Microbial Metabolite, Macro Impact: Urolithin A in the Nexus of Insulin Resistance and Colorectal Tumorigenesis. (PubMed, Nutrients)
    Human biomarker research is limited but indicates positive changes following interventions that increase UA. Future priorities include biomarker-driven, dose-finding trials stratified by metabotype, developing colon-targeted vs. systemic formulations, and testing combinations with chemotherapy and immunotherapy to determine safety and effectiveness.
    Review • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • SLC2A4 (Solute Carrier Family 2 Member 4)
    |
    5-fluorouracil
    1d
    TGF-β Receptor Inhibitor SB431542 Enhanced the Sensitivity of Gastric Cancer to 5-Fluorouracil: New Combined Targeted Therapy. (PubMed, Int J Mol Sci)
    These findings suggest that TGFBR1 inhibition could provide a strategic approach to reduce the dosage of 5FU, thereby minimizing its severe side effects in gastric cancer patients. Furthermore, these results underscore the potential of TGFBR1 as both a prognostic biomarker and a therapeutic target, warranting further investigation in aggressive forms of gastric cancer.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    5-fluorouracil